In August 2019, Oncorus announced the completion of an oversubscribed $79.5 million Series B financing. Cowen Healthcare Investments and Perceptive Advisors co-led the financing, with participation from a syndicate of blue-chip investors. To date, we have raised $140.9 million to advance our novel oncolytic platforms and a portfolio of oncolytic virus therapies to address unmet patient needs.